Literature DB >> 27916412

Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country.

Marjahan Akhtar1, Firdausi Qadri1, Taufiqur R Bhuiyan1, Sarmin Akter1, Tanzeem A Rafique1, Arifuzzaman Khan1, Laila N Islam2, Amit Saha1, Ann-Mari Svennerholm3, Anna Lundgren4.   

Abstract

Immune responses to oral enteric vaccines in children and infants may be influenced by factors such as age, previous priming with related microorganisms and breast feeding. In this study, we aimed to determine optimal time points to assess immune responses to oral enteric vaccines in different clinical specimens. This was done by investigating antibody secreting cell (ASC) and fecal antibody responses on different days after vaccination using the licensed oral cholera vaccine Dukoral, containing cholera toxin B-subunit (rCTB) and inactivated Vibrio cholerae bacteria, as a model vaccine. Two vaccine doses were given 2weeks apart to infants (6-11months), young children (12-18months), toddlers (19months-5years) and adults in a cholera endemic country (Bangladesh). IgA ASC responses, as determined by the antibodies in lymphocyte supernatant (ALS) assay, plasma IgA and IgG responses and secretory IgA (SIgA) responses in extracts of fecal samples were evaluated 4/5 and 7days after each vaccination. After the first vaccine dose, anti-CTB ALS IgA responses in adults and toddlers were high and comparable on day 5 and 7, while responses were low and infrequent in young children. After the second dose, highest ALS responses were detected on day 5 among the time points studied in all age groups and the responses declined until day 7. In contrast, plasma IgA and IgG anti-CTB responses were high both on day 5 and 7 after the second dose. Fecal SIgA responses in young children and infants were highest on day 7 after the second dose. Our results suggest that ASC/ALS responses to two doses of the oral cholera vaccine Dukoral and related oral vaccines should be analyzed earlier than previously recommended (day 7) at all ages. Fecal antibody responses should preferably be analyzed later than ASC/ALS responses to detect the highest antibody responses.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies in lymphocyte supernatant; Antibody-secreting cell; Children; Cholera; IgA; Oral vaccine

Mesh:

Substances:

Year:  2017        PMID: 27916412     DOI: 10.1016/j.vaccine.2016.11.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.

Authors:  Marjahan Akhtar; Mohiul I Chowdhury; Taufiqur R Bhuiyan; Joanna Kaim; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Yasmin A Begum; Mir Z Sharif; Laila N Islam; Nils Carlin; Nicole Maier; Alan Fix; Thomas F Wierzba; Richard I Walker; A Louis Bourgeois; Ann-Mari Svennerholm; Firdausi Qadri; Anna Lundgren
Journal:  Vaccine       Date:  2018-11-22       Impact factor: 3.641

2.  Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine.

Authors:  Fahima Chowdhury; Taufiqur Rahman Bhuiyan; Afroza Akter; Md Saruar Bhuiyan; Ashraful Islam Khan; Imam Tauheed; Tasnuva Ahmed; Jannatul Ferdous; Pinki Dash; Salima Raiyan Basher; Al Hakim; Julia Lynch; Jerome H Kim; Jean-Louis Excler; Deok Ryun Kim; John D Clemens; Firdausi Qadri
Journal:  Vaccine       Date:  2019-12-24       Impact factor: 3.641

3.  A Systems Biology Approach Identifies B Cell Maturation Antigen (BCMA) as a Biomarker Reflecting Oral Vaccine Induced IgA Antibody Responses in Humans.

Authors:  Lynda Mottram; Anna Lundgren; Ann-Mari Svennerholm; Susannah Leach
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

4.  Effectiveness of case-area targeted interventions including vaccination on the control of epidemic cholera: protocol for a prospective observational study.

Authors:  Ruwan Ratnayake; Nicolas Peyraud; Iza Ciglenecki; Etienne Gignoux; Maria Lightowler; Andrew S Azman; Primitive Gakima; Jean Patrick Ouamba; Joseph Amadomon Sagara; Rollin Ndombe; Nana Mimbu; Alexandra Ascorra; Placide Okitayemba Welo; Elisabeth Mukamba Musenga; Berthe Miwanda; Yap Boum; Francesco Checchi; W John Edmunds; Francisco Luquero; Klaudia Porten; Flavio Finger
Journal:  BMJ Open       Date:  2022-07-06       Impact factor: 3.006

5.  Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.

Authors:  Fahima Chowdhury; Taufiqur Rahman Bhuiyan; Afroza Akter; Md Saruar Bhuiyan; Ashraful Islam Khan; Motaher Hossain; Imam Tauheed; Tasnuva Ahmed; Shaumik Islam; Tanzeem Ahmed Rafique; Shah Alam Siddique; Nabila Binta Harun; Khaleda Islam; John D Clemens; Firdausi Qadri
Journal:  PLoS Negl Trop Dis       Date:  2020-03-16

6.  Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.

Authors:  Firdausi Qadri; Marjahan Akhtar; Taufiqur R Bhuiyan; Mohiul I Chowdhury; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Anna Lundgren; Gudrun Wiklund; Joanna Kaim; Madeleine Löfstrand; Nils Carlin; A Louis Bourgeois; Nicole Maier; Alan Fix; Thomas Wierzba; Richard I Walker; Ann-Mari Svennerholm
Journal:  Lancet Infect Dis       Date:  2019-11-19       Impact factor: 25.071

7.  Mucosal immune responses to Vibrio cholerae O-specific polysaccharide in adults following oral vaccination not optimally assessed.

Authors:  Susannah Leach
Journal:  Hum Vaccin Immunother       Date:  2020-03-16       Impact factor: 3.452

Review 8.  Mucosal vaccines - fortifying the frontiers.

Authors:  Ed C Lavelle; Ross W Ward
Journal:  Nat Rev Immunol       Date:  2021-07-26       Impact factor: 108.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.